Finally, MAOIs have demonstrated an anticancer effect in hormone-dependent tumors: in animal models selegiline reduced by systemic way the growth of mammary tumors [458, 459], while clorgiline reduced in vitro the growth of advanced prostate cancer (it is noteworthy that a high expression of MAO-A has been identified in high-grade primary prostate cancer) [460]. The gene discussed is MAOA; the disease is Familial prostate cancer.